VIENNA, Oct. 16, 2025 /PRNewswire/ -- Lexogen, a leader in RNA sequencing technologies, announces the launch of the miRVEL Profiling Small RNA-Seq Library Prep Kit, designed to facilitate small RNA ...
Circulating small RNAs in biofluids can serve as diagnostic and prognostic biomarkers for various diseases, such as cancer, cardiovascular and neurological disorders, and others. Biofluid samples ...
Key opportunities lie in next-generation sequencing methods, with hospitals as major end-users and North America as a ...
The prognostic value of Meet-URO score in patients with metastatic clear cell renal cell carcinoma receiving second or third-line tyrosine kinase inhibitors/immune checkpoint inhibitors combination ...
Advancing RNA therapeutics depends on understanding two critical questions: Where do drug candidates go, and what do they do ...
The landscape of next-generation sequencing (NGS) continues to be defined by astonishing technological progress. We continue ...
An individual’s genome is identifiable. But datasets of RNA sequences from single cells are like a blurry photocopy of the genome. The sequence numbers are small, the data are noisy, and the sequences ...
With the question of immunotherapeutics’ efficacy answered in the resounding affirmative, the challenge has shifted to the practical considerations of how to cost-effectively manufacture these highly ...
Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative ...
STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback